Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127020691 | 12702069 | 1 | I | 20160728 | 20160825 | 20160831 | 20160831 | EXP | GB-MHRA-EYC 00144136 | GB-DRREDDYS-GER/UKI/16/0082805 | DR REDDYS | 80.00 | YR | M | Y | 64.00000 | KG | 20160831 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127020691 | 12702069 | 1 | PS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Oral | 1000 | MG | Y | U | UNKNOWN | 75593 | 500 | MG | BID | |||
| 127020691 | 12702069 | 2 | C | LISINOPRIL. | LISINOPRIL | 1 | 0 | 10 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127020691 | 12702069 | 1 | Urinary tract infection |
| 127020691 | 12702069 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127020691 | 12702069 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127020691 | 12702069 | Myositis | |
| 127020691 | 12702069 | Pain | |
| 127020691 | 12702069 | Rash | |
| 127020691 | 12702069 | Tendonitis | |
| 127020691 | 12702069 | White blood cell count increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127020691 | 12702069 | 1 | 20160728 | 20160816 | 0 |